ASP Isotopes (NASDAQ:ASPI) CFO Heather Kiessling Sells 23,124 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CFO Heather Kiessling sold 23,124 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $5.48, for a total transaction of $126,719.52. Following the sale, the chief financial officer owned 709,376 shares of the company’s stock, valued at $3,887,380.48. This trade represents a 3.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

ASP Isotopes Stock Up 5.1%

ASP Isotopes stock opened at $5.37 on Friday. The firm has a market capitalization of $676.08 million, a price-to-earnings ratio of -2.51 and a beta of 3.59. The firm’s fifty day moving average price is $5.06 and its two-hundred day moving average price is $6.73. ASP Isotopes Inc. has a 1-year low of $3.92 and a 1-year high of $14.49. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04.

ASP Isotopes (NASDAQ:ASPI) last posted its earnings results on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.70). ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%.The business had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million. On average, equities research analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ASPI has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price target on shares of ASP Isotopes in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sara Bay Financial purchased a new position in shares of ASP Isotopes in the 1st quarter worth approximately $2,593,000. SG Americas Securities LLC purchased a new position in ASP Isotopes in the first quarter worth $433,000. Allegheny Financial Group grew its stake in ASP Isotopes by 17.9% in the 1st quarter. Allegheny Financial Group now owns 40,649 shares of the company’s stock valued at $180,000 after purchasing an additional 6,176 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of ASP Isotopes by 177.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 34,983 shares of the company’s stock valued at $187,000 after purchasing an additional 22,361 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of ASP Isotopes during the 4th quarter worth $2,163,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.